Skip to main content
Erschienen in: Current Oncology Reports 1/2012

01.02.2012 | Neuro-oncology (M Gilbert, Section Editor)

Epidemiology of Brain Metastases

verfasst von: Lakshmi Nayak, Eudocia Quant Lee, Patrick Y. Wen

Erschienen in: Current Oncology Reports | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Brain metastases are one of the most common neurologic complications of cancer. The incidence is 9%–17% based on various studies, although the exact incidence is thought to be higher. The incidence is increasing with the availability of improved imaging techniques which aid early diagnosis, and effective systemic treatment regimens which prolong life, thus allowing cancer to disseminate to the brain. Lung cancer, breast cancer, and melanoma are the most frequent to develop brain metastases, and account for 67%–80% of all cancers. Most patients with brain metastases have synchronous extracerebral metastases. Some patients present with no known primary cancer diagnosis. In children, brain metastases are rare; germ cell tumors, sarcomas, and neuroblastoma are the common offenders.
Literatur
1.
Zurück zum Zitat • DeAngelis LM, Posner JB. Intracranial metastases. In: DeAngelis LM, Posner JB, editors. Neurologic complications of cancer. New York: Oxford University Press; 2009. p. 141–193. This book is the most comprehensive review of neurologic complications of cancer, including intracranial metastases. • DeAngelis LM, Posner JB. Intracranial metastases. In: DeAngelis LM, Posner JB, editors. Neurologic complications of cancer. New York: Oxford University Press; 2009. p. 141–193. This book is the most comprehensive review of neurologic complications of cancer, including intracranial metastases.
2.
Zurück zum Zitat Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am. 1996;7:337–44.PubMed Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am. 1996;7:337–44.PubMed
3.
Zurück zum Zitat Barker 2nd FG. Craniotomy for the resection of metastatic brain tumors in the U.S., 1988–2000: decreasing mortality and the effect of provider caseload. Cancer. 2004;100:999–1007.PubMedCrossRef Barker 2nd FG. Craniotomy for the resection of metastatic brain tumors in the U.S., 1988–2000: decreasing mortality and the effect of provider caseload. Cancer. 2004;100:999–1007.PubMedCrossRef
4.
Zurück zum Zitat Percy AK, Elveback LR, Okazaki H, Kurland LT. Neoplasms of the central nervous system. Epidemiologic considerations. Neurology. 1972;22:40–8.PubMed Percy AK, Elveback LR, Okazaki H, Kurland LT. Neoplasms of the central nervous system. Epidemiologic considerations. Neurology. 1972;22:40–8.PubMed
5.
Zurück zum Zitat Walker AE, Robins M, Weinfeld FD. Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology. 1985;35:219–26.PubMed Walker AE, Robins M, Weinfeld FD. Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology. 1985;35:219–26.PubMed
6.
Zurück zum Zitat Counsell CE, Collie DA, Grant R. Incidence of intracranial tumours in the Lothian region of Scotland, 1989–90. J Neurol Neurosurg Psychiatry. 1996;61:143–50.PubMedCrossRef Counsell CE, Collie DA, Grant R. Incidence of intracranial tumours in the Lothian region of Scotland, 1989–90. J Neurol Neurosurg Psychiatry. 1996;61:143–50.PubMedCrossRef
7.
Zurück zum Zitat Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94:2698–705.PubMedCrossRef Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94:2698–705.PubMedCrossRef
8.
Zurück zum Zitat Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22:2865–72.PubMedCrossRef Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22:2865–72.PubMedCrossRef
9.
Zurück zum Zitat Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol. 1978;19:579–92.PubMed Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol. 1978;19:579–92.PubMed
10.
Zurück zum Zitat Takakura K, Sano K, Hojo S, Hirano A. Metastatic tumors of the central nervous system. Tokyo: Igaku-Shoin; 1982. Takakura K, Sano K, Hojo S, Hirano A. Metastatic tumors of the central nervous system. Tokyo: Igaku-Shoin; 1982.
11.
Zurück zum Zitat Pickren JW, Lopez G, Tsukada Y, Lane WW. Brain metastases: an autopsy study. Cancer Treat Symp. 1983;2:295–313. Pickren JW, Lopez G, Tsukada Y, Lane WW. Brain metastases: an autopsy study. Cancer Treat Symp. 1983;2:295–313.
12.
Zurück zum Zitat • Fabi A, Felici A, Metro G et al. Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. J Exp Clin Cancer Res. 2011;30:10. This survey provides recent data from four Italian cancer centers on brain metastases from solid tumors.PubMedCrossRef • Fabi A, Felici A, Metro G et al. Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. J Exp Clin Cancer Res. 2011;30:10. This survey provides recent data from four Italian cancer centers on brain metastases from solid tumors.PubMedCrossRef
13.
Zurück zum Zitat Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer. 2004;91:639–43.PubMed Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer. 2004;91:639–43.PubMed
14.
Zurück zum Zitat Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97:2972–7.PubMedCrossRef Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97:2972–7.PubMedCrossRef
15.
16.
Zurück zum Zitat Stemmler HJ, Kahlert S, Siekiera W, et al. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast. 2006;15:219–25.PubMedCrossRef Stemmler HJ, Kahlert S, Siekiera W, et al. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast. 2006;15:219–25.PubMedCrossRef
17.
Zurück zum Zitat Yau T, Swanton C, Chua S, et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol. 2006;45:196–201.PubMedCrossRef Yau T, Swanton C, Chua S, et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol. 2006;45:196–201.PubMedCrossRef
18.
Zurück zum Zitat Stark AM, Stohring C, Hedderich J, et al. Surgical treatment for brain metastases: Prognostic factors and survival in 309 patients with regard to patient age. J Clin Neurosci. 2011;18:34–8.PubMedCrossRef Stark AM, Stohring C, Hedderich J, et al. Surgical treatment for brain metastases: Prognostic factors and survival in 309 patients with regard to patient age. J Clin Neurosci. 2011;18:34–8.PubMedCrossRef
19.
Zurück zum Zitat Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer. 1996;78:1781–8.PubMedCrossRef Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer. 1996;78:1781–8.PubMedCrossRef
20.
Zurück zum Zitat Delattre JY, Krol G, Thaler HT, Posner JB. Distribution of brain metastases. Arch Neurol. 1988;45:741–4.PubMedCrossRef Delattre JY, Krol G, Thaler HT, Posner JB. Distribution of brain metastases. Arch Neurol. 1988;45:741–4.PubMedCrossRef
21.
Zurück zum Zitat Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494–500.PubMedCrossRef Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494–500.PubMedCrossRef
22.
Zurück zum Zitat Graf AH, Buchberger W, Langmayr H, Schmid KW. Site preference of metastatic tumours of the brain. Virchows Arch A Pathol Anat Histopathol. 1988;412:493–8.PubMedCrossRef Graf AH, Buchberger W, Langmayr H, Schmid KW. Site preference of metastatic tumours of the brain. Virchows Arch A Pathol Anat Histopathol. 1988;412:493–8.PubMedCrossRef
23.
Zurück zum Zitat Lagerwaard FJ, Levendag PC, Nowak PJ, et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999;43:795–803.PubMedCrossRef Lagerwaard FJ, Levendag PC, Nowak PJ, et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999;43:795–803.PubMedCrossRef
24.
Zurück zum Zitat Ruda R, Borgognone M, Benech F, et al. Brain metastases from unknown primary tumour: a prospective study. J Neurol. 2001;248:394–8.PubMedCrossRef Ruda R, Borgognone M, Benech F, et al. Brain metastases from unknown primary tumour: a prospective study. J Neurol. 2001;248:394–8.PubMedCrossRef
25.
Zurück zum Zitat Mavrakis AN, Halpern EF, Barker 2nd FG, et al. Diagnostic evaluation of patients with a brain mass as the presenting manifestation of cancer. Neurology. 2005;65:908–11.PubMedCrossRef Mavrakis AN, Halpern EF, Barker 2nd FG, et al. Diagnostic evaluation of patients with a brain mass as the presenting manifestation of cancer. Neurology. 2005;65:908–11.PubMedCrossRef
26.
Zurück zum Zitat • Vuong DA, Rades D, Vo SQ, Busse R. Extracranial metastatic patterns on occurrence of brain metastases. J Neurooncol. 2011. This study evaluates a large number of patients with brain metastases and provides data on the pattern of metastases outside the brain. • Vuong DA, Rades D, Vo SQ, Busse R. Extracranial metastatic patterns on occurrence of brain metastases. J Neurooncol. 2011. This study evaluates a large number of patients with brain metastases and provides data on the pattern of metastases outside the brain.
27.
Zurück zum Zitat • Hubbs JL, Boyd JA, Hollis D et al. Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. Cancer. 2010;116:5038–5046. This is a recent retrospective review evaluating the risk factors in patients with NSCLC in the development of brain metastases.PubMedCrossRef • Hubbs JL, Boyd JA, Hollis D et al. Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. Cancer. 2010;116:5038–5046. This is a recent retrospective review evaluating the risk factors in patients with NSCLC in the development of brain metastases.PubMedCrossRef
28.
Zurück zum Zitat Shi AA, Digumarthy SR, Temel JS, et al. Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer? J Thorac Oncol. 2006;1:205–10.PubMed Shi AA, Digumarthy SR, Temel JS, et al. Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer? J Thorac Oncol. 2006;1:205–10.PubMed
29.
Zurück zum Zitat Chen AM, Jahan TM, Jablons DM, et al. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain. Cancer. 2007;109:1668–75.PubMedCrossRef Chen AM, Jahan TM, Jablons DM, et al. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain. Cancer. 2007;109:1668–75.PubMedCrossRef
30.
Zurück zum Zitat Hung JJ, Jeng WJ, Hsu WH, et al. Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis. Thorax. 2010;65:241–5.PubMedCrossRef Hung JJ, Jeng WJ, Hsu WH, et al. Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis. Thorax. 2010;65:241–5.PubMedCrossRef
31.
Zurück zum Zitat Tomlinson BE, Perry RH, Stewart-Wynne EG. Influence of site of origin of lung carcinomas on clinical presentation and central nervous system metastases. J Neurol Neurosurg Psychiatry. 1979;42:82–8.PubMedCrossRef Tomlinson BE, Perry RH, Stewart-Wynne EG. Influence of site of origin of lung carcinomas on clinical presentation and central nervous system metastases. J Neurol Neurosurg Psychiatry. 1979;42:82–8.PubMedCrossRef
32.
Zurück zum Zitat Yawn BP, Wollan PC, Schroeder C, et al. Temporal and gender-related trends in brain metastases from lung and breast cancer. Minn Med. 2003;86:32–7.PubMed Yawn BP, Wollan PC, Schroeder C, et al. Temporal and gender-related trends in brain metastases from lung and breast cancer. Minn Med. 2003;86:32–7.PubMed
33.
Zurück zum Zitat Heon S, Yeap BY, Britt GJ, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010;16:5873–82.PubMedCrossRef Heon S, Yeap BY, Britt GJ, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010;16:5873–82.PubMedCrossRef
34.
Zurück zum Zitat Seute T, Leffers P, Wilmink JT, et al. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J Clin Oncol. 2006;24:2079–83.PubMedCrossRef Seute T, Leffers P, Wilmink JT, et al. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J Clin Oncol. 2006;24:2079–83.PubMedCrossRef
35.
Zurück zum Zitat Greenspoon JN, Evans WK, Cai W, Wright JR. Selecting patients with extensive-stage small cell lung cancer for prophylactic cranial irradiation by predicting brain metastases. J Thorac Oncol. 2011;6:808–12.PubMedCrossRef Greenspoon JN, Evans WK, Cai W, Wright JR. Selecting patients with extensive-stage small cell lung cancer for prophylactic cranial irradiation by predicting brain metastases. J Thorac Oncol. 2011;6:808–12.PubMedCrossRef
36.
Zurück zum Zitat Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664–72.PubMedCrossRef Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664–72.PubMedCrossRef
37.
Zurück zum Zitat Stemmler HJ, Heinemann V. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist. 2008;13:739–50.PubMedCrossRef Stemmler HJ, Heinemann V. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist. 2008;13:739–50.PubMedCrossRef
38.
Zurück zum Zitat Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006;17:935–44.PubMedCrossRef Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006;17:935–44.PubMedCrossRef
39.
Zurück zum Zitat Gonzalez-Angulo AM, Cristofanilli M, Strom EA, et al. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer. 2004;101:1760–6.PubMedCrossRef Gonzalez-Angulo AM, Cristofanilli M, Strom EA, et al. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer. 2004;101:1760–6.PubMedCrossRef
40.
Zurück zum Zitat Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22:3608–17.PubMedCrossRef Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22:3608–17.PubMedCrossRef
41.
Zurück zum Zitat Dawood S, Broglio K, Esteva FJ, et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol. 2009;20:621–7.PubMedCrossRef Dawood S, Broglio K, Esteva FJ, et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol. 2009;20:621–7.PubMedCrossRef
42.
Zurück zum Zitat Anders CK, Deal AM, Miller CR, et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer. 2011;117:1602–11.PubMedCrossRef Anders CK, Deal AM, Miller CR, et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer. 2011;117:1602–11.PubMedCrossRef
43.
Zurück zum Zitat Albiges L, Andre F, Balleyguier C, et al. Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. Ann Oncol. 2005;16:1846–7.PubMedCrossRef Albiges L, Andre F, Balleyguier C, et al. Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. Ann Oncol. 2005;16:1846–7.PubMedCrossRef
44.
Zurück zum Zitat Gabos Z, Sinha R, Hanson J, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol. 2006;24:5658–63.PubMedCrossRef Gabos Z, Sinha R, Hanson J, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol. 2006;24:5658–63.PubMedCrossRef
45.
Zurück zum Zitat • Musolino A, Ciccolallo L, Panebianco M et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer. 2011;117:1837–1846. This is the first population-based study evaluating the relationship of HER2-positive patients and use of trastuzumab in the development of brain metastases. PubMedCrossRef • Musolino A, Ciccolallo L, Panebianco M et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer. 2011;117:1837–1846. This is the first population-based study evaluating the relationship of HER2-positive patients and use of trastuzumab in the development of brain metastases. PubMedCrossRef
46.
Zurück zum Zitat Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol. 2009;27:5278–86.PubMedCrossRef Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol. 2009;27:5278–86.PubMedCrossRef
47.
Zurück zum Zitat Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29–36.PubMedCrossRef Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29–36.PubMedCrossRef
48.
Zurück zum Zitat Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.PubMedCrossRef Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.PubMedCrossRef
49.
Zurück zum Zitat • Bria E, Cuppone F, Fornier M et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat. 2008;109:231–239. This provides a review of the three major randomized phase 3 trials using trastuzumab and a meta-analysis of those trials.PubMedCrossRef • Bria E, Cuppone F, Fornier M et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat. 2008;109:231–239. This provides a review of the three major randomized phase 3 trials using trastuzumab and a meta-analysis of those trials.PubMedCrossRef
50.
Zurück zum Zitat Sul J, Posner JB. Brain metastases: epidemiology and pathophysiology. Cancer Treat Res. 2007;136:1–21.PubMedCrossRef Sul J, Posner JB. Brain metastases: epidemiology and pathophysiology. Cancer Treat Res. 2007;136:1–21.PubMedCrossRef
51.
Zurück zum Zitat Dasgupta T, Brasfield R. Metastatic melanoma. A clinicopathological study. Cancer. 1964;17:1323–39.PubMedCrossRef Dasgupta T, Brasfield R. Metastatic melanoma. A clinicopathological study. Cancer. 1964;17:1323–39.PubMedCrossRef
52.
Zurück zum Zitat Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg. 1978;135:807–10.PubMedCrossRef Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg. 1978;135:807–10.PubMedCrossRef
53.
Zurück zum Zitat de la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res. 1983;43:3427–33.PubMed de la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res. 1983;43:3427–33.PubMed
54.
Zurück zum Zitat Sampson JH, Carter Jr JH, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88:11–20.PubMedCrossRef Sampson JH, Carter Jr JH, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88:11–20.PubMedCrossRef
55.
Zurück zum Zitat Zakrzewski J, Geraghty LN, Rose AE, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer. 2011;117:1711–20.PubMedCrossRef Zakrzewski J, Geraghty LN, Rose AE, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer. 2011;117:1711–20.PubMedCrossRef
56.
Zurück zum Zitat Daryanani D, Plukker JT, de Jong MA, et al. Increased incidence of brain metastases in cutaneous head and neck melanoma. Melanoma Res. 2005;15:119–124.57.PubMedCrossRef Daryanani D, Plukker JT, de Jong MA, et al. Increased incidence of brain metastases in cutaneous head and neck melanoma. Melanoma Res. 2005;15:119–124.57.PubMedCrossRef
57.
Zurück zum Zitat Raizer JJ, Hwu WJ, Panageas KS, et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol. 2008;10:199–207.PubMedCrossRef Raizer JJ, Hwu WJ, Panageas KS, et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol. 2008;10:199–207.PubMedCrossRef
58.
Zurück zum Zitat Wronski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg. 2000;93:9–18.PubMedCrossRef Wronski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg. 2000;93:9–18.PubMedCrossRef
59.
Zurück zum Zitat Liew DN, Kano H, Kondziolka D, et al. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg. 2011;114:769–79.PubMedCrossRef Liew DN, Kano H, Kondziolka D, et al. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg. 2011;114:769–79.PubMedCrossRef
60.
Zurück zum Zitat Miyao N, Naito S, Ozono S, et al. Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer. Urology. 2011;77:379–84.PubMedCrossRef Miyao N, Naito S, Ozono S, et al. Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer. Urology. 2011;77:379–84.PubMedCrossRef
61.
Zurück zum Zitat Wronski M, Arbit E, Russo P, Galicich JH. Surgical resection of brain metastases from renal cell carcinoma in 50 patients. Urology. 1996;47:187–93.PubMedCrossRef Wronski M, Arbit E, Russo P, Galicich JH. Surgical resection of brain metastases from renal cell carcinoma in 50 patients. Urology. 1996;47:187–93.PubMedCrossRef
62.
Zurück zum Zitat Mongan JP, Fadul CE, Cole BF, et al. Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Colorectal Cancer. 2009;8:100–5.CrossRef Mongan JP, Fadul CE, Cole BF, et al. Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Colorectal Cancer. 2009;8:100–5.CrossRef
63.
Zurück zum Zitat Kruser TJ, Chao ST, Elson P, et al. Multidisciplinary management of colorectal brain metastases: a retrospective study. Cancer. 2008;113:158–65.PubMedCrossRef Kruser TJ, Chao ST, Elson P, et al. Multidisciplinary management of colorectal brain metastases: a retrospective study. Cancer. 2008;113:158–65.PubMedCrossRef
64.
Zurück zum Zitat Nieder C, Pawinski A, Balteskard L. Colorectal cancer metastatic to the brain: time trends in presentation and outcome. Oncology. 2009;76:369–74.PubMedCrossRef Nieder C, Pawinski A, Balteskard L. Colorectal cancer metastatic to the brain: time trends in presentation and outcome. Oncology. 2009;76:369–74.PubMedCrossRef
65.
Zurück zum Zitat Giordana MT, Cordera S, Boghi A. Cerebral metastases as first symptom of cancer: a clinico-pathologic study. J Neurooncol. 2000;50:265–73.PubMedCrossRef Giordana MT, Cordera S, Boghi A. Cerebral metastases as first symptom of cancer: a clinico-pathologic study. J Neurooncol. 2000;50:265–73.PubMedCrossRef
66.
Zurück zum Zitat Bouffet E, Doumi N, Thiesse P, et al. Brain metastases in children with solid tumors. Cancer. 1997;79:403–10.PubMedCrossRef Bouffet E, Doumi N, Thiesse P, et al. Brain metastases in children with solid tumors. Cancer. 1997;79:403–10.PubMedCrossRef
67.
Zurück zum Zitat Kebudi R, Ayan I, Gorgun O, et al. Brain metastasis in pediatric extracranial solid tumors: survey and literature review. J Neurooncol. 2005;71:43–8.PubMedCrossRef Kebudi R, Ayan I, Gorgun O, et al. Brain metastasis in pediatric extracranial solid tumors: survey and literature review. J Neurooncol. 2005;71:43–8.PubMedCrossRef
68.
69.
Zurück zum Zitat Curless RG, Toledano SR, Ragheb J, et al. Hematogenous brain metastasis in children. Pediatr Neurol. 2002;26:219–21.PubMedCrossRef Curless RG, Toledano SR, Ragheb J, et al. Hematogenous brain metastasis in children. Pediatr Neurol. 2002;26:219–21.PubMedCrossRef
70.
Zurück zum Zitat Kramer K, Kushner B, Heller G, Cheung NK. Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-kettering Cancer Center experience and a literature review. Cancer. 2001;91:1510–9.PubMedCrossRef Kramer K, Kushner B, Heller G, Cheung NK. Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-kettering Cancer Center experience and a literature review. Cancer. 2001;91:1510–9.PubMedCrossRef
Metadaten
Titel
Epidemiology of Brain Metastases
verfasst von
Lakshmi Nayak
Eudocia Quant Lee
Patrick Y. Wen
Publikationsdatum
01.02.2012
Verlag
Current Science Inc.
Erschienen in
Current Oncology Reports / Ausgabe 1/2012
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-011-0203-y

Weitere Artikel der Ausgabe 1/2012

Current Oncology Reports 1/2012 Zur Ausgabe

Neuro-oncology (M Gilbert, Section Editor)

Treatment of Brain Metastases: Chemotherapy

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.